Eli Lilly recently announced encouraging Phase 1 results for its ovarian cancer treatment using a folate receptor alpha ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong sales from products outside of diabetes and obesity care. Eli Lilly's ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose ...

Nxera Pharma just hit a milestone in its collaboration with Eli Lilly, unlocking a confidential payment expected by late 2025. This achievement significantly boosts Nxera’s research efforts in ...